Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML - PubMed (original) (raw)
. 2004 Oct 15;104(8):2532-9.
doi: 10.1182/blood-2004-05-1851. Epub 2004 Jul 15.
Roy Pollock, Eric P Stoffregen, Jeffrey A Keats, Omar M Abdullah, Erika M Moseson, Victor M Rivera, Hao Tang, Chester A Metcalf 3rd, Regine S Bohacek, Yihan Wang, Raji Sundaramoorthi, William C Shakespeare, David Dalgarno, Tim Clackson, Tomi K Sawyer, Michael W Deininger, Brian J Druker
Affiliations
- PMID: 15256422
- DOI: 10.1182/blood-2004-05-1851
Free article
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
Thomas O'Hare et al. Blood. 2004.
Free article
Abstract
The deregulated, oncogenic tyrosine kinase Bcr-Abl causes chronic myeloid leukemia (CML). Imatinib mesylate (Gleevec, STI571), a Bcr-Abl kinase inhibitor, selectively inhibits proliferation and promotes apoptosis of CML cells. Despite the success of imatinib mesylate in the treatment of CML, resistance is observed, particularly in advanced disease. The most common imatinib mesylate resistance mechanism involves Bcr-Abl kinase domain mutations that impart varying degrees of drug insensitivity. AP23464, a potent adenosine 5'-triphosphate (ATP)-based inhibitor of Src and Abl kinases, displays antiproliferative activity against a human CML cell line and Bcr-Abl-transduced Ba/F3 cells (IC(50) = 14 nM; imatinib mesylate IC(50) = 350 nM). AP23464 ablates Bcr-Abl tyrosine phosphorylation, blocks cell cycle progression, and promotes apoptosis of Bcr-Abl-expressing cells. Biochemical assays with purified glutathione S transferase (GST)-Abl kinase domain confirmed that AP23464 directly inhibits Abl activity. Importantly, the low nanomolar cellular and biochemical inhibitory properties of AP23464 extend to frequently observed imatinib mesylate-resistant Bcr-Abl mutants, including nucleotide binding P-loop mutants Q252H, Y253F, E255K, C-terminal loop mutant M351T, and activation loop mutant H396P. AP23464 was ineffective against mutant T315I, an imatinib mesylate contact residue. The potency of AP23464 against imatinib mesylate-refractory Bcr-Abl and its distinct binding mode relative to imatinib mesylate warrant further investigation of AP23464 for the treatment of CML.
Similar articles
- Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
Wu LX, Wu Y, Chen RJ, Liu Y, Huang LS, Lou LG, Zheng ZH, Chen YZ, Xu JH. Wu LX, et al. Acta Pharmacol Sin. 2014 Mar;35(3):401-9. doi: 10.1038/aps.2013.180. Epub 2014 Feb 3. Acta Pharmacol Sin. 2014. PMID: 24487968 Free PMC article. - Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
von Bubnoff N, Veach DR, Miller WT, Li W, Sänger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. von Bubnoff N, et al. Cancer Res. 2003 Oct 1;63(19):6395-404. Cancer Res. 2003. PMID: 14559829 - Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K. Nimmanapalli R, et al. Cancer Res. 2002 Oct 15;62(20):5761-9. Cancer Res. 2002. PMID: 12384536 - Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
Nimmanapalli R, Bhalla K. Nimmanapalli R, et al. Curr Opin Oncol. 2002 Nov;14(6):616-20. doi: 10.1097/00001622-200211000-00005. Curr Opin Oncol. 2002. PMID: 12409651 Review. - The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
Maekawa T, Ashihara E, Kimura S. Maekawa T, et al. Int J Clin Oncol. 2007 Oct;12(5):327-40. doi: 10.1007/s10147-007-0699-1. Epub 2007 Oct 22. Int J Clin Oncol. 2007. PMID: 17929114 Review.
Cited by
- Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Azam M, Nardi V, Shakespeare WC, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ. Azam M, et al. Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9244-9. doi: 10.1073/pnas.0600001103. Epub 2006 Jun 5. Proc Natl Acad Sci U S A. 2006. PMID: 16754879 Free PMC article. - Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.
Peng C, Brain J, Hu Y, Goodrich A, Kong L, Grayzel D, Pak R, Read M, Li S. Peng C, et al. Blood. 2007 Jul 15;110(2):678-85. doi: 10.1182/blood-2006-10-054098. Epub 2007 Mar 29. Blood. 2007. PMID: 17395781 Free PMC article. - Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
Tseng PH, Lin HP, Zhu J, Chen KF, Hade EM, Young DC, Byrd JC, Grever M, Johnson K, Druker BJ, Chen CS. Tseng PH, et al. Blood. 2005 May 15;105(10):4021-7. doi: 10.1182/blood-2004-07-2967. Epub 2005 Jan 21. Blood. 2005. PMID: 15665113 Free PMC article. - Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.
Agarwal A, Bumm TG, Corbin AS, O'Hare T, Loriaux M, VanDyke J, Willis SG, Deininger J, Nakayama KI, Druker BJ, Deininger MW. Agarwal A, et al. Blood. 2008 Sep 1;112(5):1960-70. doi: 10.1182/blood-2007-09-113860. Epub 2008 Jun 17. Blood. 2008. PMID: 18559973 Free PMC article. - NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor.
Niwa T, Asaki T, Kimura S. Niwa T, et al. Anal Chem Insights. 2007 Nov 14;2:93-106. Anal Chem Insights. 2007. PMID: 19662183 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous